Volume | 1,489,147 |
|
|||||
News | - | ||||||
Day High | 14.60 | Low High |
|||||
Day Low | 13.64 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Nurix Therapeutics Inc | NRIX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
14.11 | 13.64 | 14.60 | 14.44 | 14.08 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
11,650 | 1,489,147 | $ 14.28 | $ 21,272,402 | - | 4.22 - 18.12 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:33:37 | priorref | 516,192 | $ 14.44 | USD |
Nurix Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
706.03M | 48.89M | - | 76.99M | -143.95M | -2.94 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Nurix Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NRIX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 17.09 | 18.12 | 13.64 | 15.78 | 2,138,070 | -2.65 | -15.51% |
1 Month | 13.48 | 18.12 | 12.55 | 15.30 | 1,327,005 | 0.96 | 7.12% |
3 Months | 7.77 | 18.12 | 7.65 | 13.22 | 1,002,675 | 6.67 | 85.84% |
6 Months | 6.01 | 18.12 | 4.22 | 10.62 | 879,288 | 8.43 | 140.27% |
1 Year | 13.28 | 18.12 | 4.22 | 10.24 | 606,733 | 1.16 | 8.73% |
3 Years | 28.76 | 37.425 | 4.22 | 15.15 | 475,990 | -14.32 | -49.79% |
5 Years | 20.25 | 52.38 | 4.22 | 17.68 | 442,246 | -5.81 | -28.69% |
Nurix Therapeutics Description
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications. |